Skip to main
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is positioned for a positive outlook due to its robust pipeline, particularly with the drug candidate CGT9486, which has demonstrated significant efficacy in treating Systemic Mastocytosis and advanced gastrointestinal stromal tumors. Data from recent clinical trials show a substantial reduction in disease progression and symptom burden, reinforcing confidence in the drug's potential approval and market impact. The company's strong balance sheet supports both commercialization efforts and further pipeline development, highlighting the opportunity for significant revenue growth as they advance towards potential drug approvals.

Bears say

Cogent Biosciences faces significant risks impacting its financial outlook, primarily due to the potential for poorer-than-expected clinical results from its CGT9486 program, which could lead to downward adjustments in market penetration and longer timelines to regulatory approval. Additional concerns include competition from superior products, regulatory challenges, slower development timelines, and the possibility of dilution. These factors collectively contribute to uncertainty surrounding the company's commercial success and overall valuation.

COGT has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 11 analysts, COGT has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.